37 results about "Newly diagnosed" patented technology

We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier was also validated by qPCR in thirty AML samples from the same clinical study demonstrating a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50%, respectively (odds ratio of 4.3). These data indicate that a simple two-gene expression assay may have utility in diagnosing a population of AML patients who are more likely to respond to tipifarnib.

The invention relates to an evaluation system and method for the efficacy of synchro-neoadjuvant chemoradiotherapy before the rectal cancer surgery. The evaluation system comprises an image acquisition unit used for acquiring pathological biopsy slice scan images and neoadjuvant chemoradiotherapy treatment pre-MRI images of newly diagnosed locally advanced rectal cancer patients, and classifying the rectal cancer patients into a training set, a check set and a test set, to serve as input image data, an image labeling unit used for respectively labeling the pathological biopsy slice scan imagesand the MRI images of the training set, the check set and the test set, a convolutional neural network constructing unit used for constructing a first convolutional neural network model, and a convolutional neural network model training unit used for obtaining a second convolutional neural network model for evaluating the efficacy of synchro-neoadjuvant chemoradiotherapy before the rectal cancersurgery. The evaluation system for the efficacy of synchro-neoadjuvant chemoradiotherapy before the rectal cancer surgery has multiple advantages such as being high in accuracy, short in time consumption, long in working duration, objective and three-dimensional.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

The invention discloses a medical service guiding system based on patient physical symptoms. The medical service guiding system comprises a client side system and a server system, wherein the client side system and the server system are connected with each other through a network. The client side system comprises a doctor information module, a department information module, a disease inquiry module, a symptom fuzzy reasoning module, a human body system guiding module, a human body part guiding module, a laboratory result module and a hospital planar graph module. Users can log into the medical service guiding system through a hospital terminal device or a personal handheld mobile device and select the corresponding modules to conduct inquiry; meanwhile, by setting up a symptom-department-doctor fuzzy reasoning model, newly-diagnosed patients can be helped to rapidly know prevalence of themselves according to the symptoms of themselves and find appropriate doctors in the unfamiliar environment, and therefore flexibility, accuracy and diagnostic efficiency are improved compared with an existing system. By means of the medical service guiding system, the current requirement of people for medical treatment and health is met, and the hospital service level and the service capacity are improved.

The present invention discloses a method of applying novel bioinformatics and computational methodologies to data generated by high-resolution genome-wide comparative genomic hybridization and gene expression profiling on CD138-sorted plasma cells from a cohort of 92 newly diagnosed multiple myeloma patients treated with high dose chemotherapy and stem cell rescue. The results revealed that gains the q arm and loss of the p arm of chromosome 1 were highly correlated with altered expression of resident genes in this chromosome, with these changes strongly correlated with 1) risk of death from disease progression, 2) a gene expression based proliferation index, and 3) a recently described gene expression-based high-risk index. Importantly, we also found a strong correlation between copy number gains of 8q24, and increased expression of Argonate 2 (AGO2) a gene coding for a master regulator of microRNA expression and maturation, also being significantly correlated with outcome. Our novel findings significantly improve our understanding of the genomic structure of multiple myeloma and its relationship to clinical outcome.

The present disclosure describes methods for treating or preventing Type 1 diabetes mellitus in juveniles, particularly in juveniles newly diagnosed with Type 1 diabetes. This prevention or treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin, thereby decreasing the destruction of islet cells, or maintaining endogenous insulin production, in the juvenile.

The invention discloses a device for predicting the bone metastasis risk of newly-diagnosed prostate cancer. According to the device, the risk of bone metastasis is predicted, bone scanning is carried out on patients with high bone metastasis risk and the overuse of the bone scanning is avoided under the condition of not increasing missed diagnosis. The technical scheme provided by the invention is that the device comprises a storage module, four input modules, a processing module and an output module, wherein four input slots are formed in the storage module and are a slot with fixed length, a first slot for sliding, a second slot for sliding and a third slot for sliding respectively; the four input modules are a clinical stage input module placed in the slot with the fixed length, a Gleason scoring input module placed in the first slot for sliding, a PSA (Prostate-Specific Antigen) value input module placed in the second slot for sliding and an age input module placed in the third slot for sliding; the processing module is used for adjusting the positions of the four input modules in the input slots of the storage module to obtain an output locus; and the output module is provided with a staff gauge for predicting a risk value of the bone metastasis, and a corresponding locus of the output locus on the staff gauge is a predicted risk value.

The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease reduce tumor burden in multiple myeloma and to block bone disease.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

The invention relates to a kit for detecting an expression index of mRNA (messager Ribose Nucleic Acid) of a WT1 (Wilms Tumor 1) gene, and belongs to the field of biotechnology. The kit comprises detection primers, a fluorescent probe, a cDNA (complementary Deoxyribose Nucleic Acid) first strand synthesis reagent, a fluorescent quantitative PCR (Polymerase Chain Reaction) mixed solution, negative reference and positive reference, wherein the detection primers and the fluorescent probe comprise a WT1 gene primer, an internal reference gene ABL primer and a Taqman fluorescent probe. The WT1 gene is related with hematopoietic tumor incidence, is of over-expression in about 80% of patients with newly diagnosed acute myelocytic leukemia and acute lymphocytic leukemia, is recognized as a leukemia marker gene, and can serve as an independent minimal residue disease monitoring and prognosis prompting index. The level of the mRNA of the WT1 gene is detected by adopting a fluorescent quantitative PCR technology with higher sensitivity and specificity, and both the specificity and the sensitivity of a detection result are remarkably improved. The kit provides a brand-new quick, simple and convenient gene diagnosis technology for prognosing the acute myelocytic leukemia and the acute lymphocytic leukemia and confirming chemotherapy regimens.

YKL-40 levels in serum and plasma samples provide as an indicator of both the presence of early stage ovarian cancer and of its aggressiveness. Thus testing for YKL-40 levels in patients at risk but not yet displaying symptoms associated with ovarian cancer, or in patients newly diagnosed with early stage ovarian cancer (Stage I or II) enhance both the detection of early stage ovarian cancer and selection of treatment protocols used for early stage ovarian cancer patients.

To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes.

The invention discloses a device for predicting a prostate cancer risk in prostate aspiration biopsy. The risk of prostate cancer is predicted in advance, prostate biopsy is only carried out on patients is avoided under the condition that missed diagnosis is not increased, and thus unnecessary biopsy of biopsy patients is reduced. According to the technical scheme, related clinical clinicopathologic data of newly-diagnosed prostate aspiration biopsy patients is subjected to retrospective analysis, a prediction nomographic chart of related prediction indexes is established, and accordingly the device convenient to use clinically is designed. By means of the device, clinical doctors can predict the probability of newly-diagnosed prostate aspiration biopsy cancer according to three clinical indexes, namely, prostate health index numerical values, the prostate volume and the age of patients.

The invention provides application of isoalantolactone in preparation of medicines for resisting chronic myeloid leukemia by screening cell lines with built GFP-Bcr-Abl. The inventor finds out that the anti-CML activity of the isoalantolactone is realized by specifically inducing autolysosome in a K562 cell to actively degrade Bcr-Abl fusion protein, and simultaneously finds out that the isoalantolactone is capable of significantly inhibiting formation of Bcr-Abl positive stem cell cloning in newly diagnosed chronic myeloid patients and medicine-resistant patients. The possibility is provided for treatment medicine-resistant or recurrent CML patients by inducing degradation of the Bcr-Abl fusion protein through a natural small molecular compound of the isoalantolactone.

The invention discloses a soft capsule for treating intracorporeal stones and relates to the field of health care products, the stone symptoms have various types, the causes are different, the traditional Chinese medicine uses different formulas to treat different stone symptoms, the prescribe is difficult to suit the symptoms of newly diagnosed patients, an appropriate formula is more difficult to be selected for the prevention, so a broad-spectrum formula is needed to avoid the difficulty of selection, the soft capsule is proposed for solving the problem, the soft capsule adopts ten materials including chicken's gizzard-membrane, honeysuckle flower, hawthorn fruit, lucid ganoderma, fennel fruit, corn stigma, and the like, the soft capsule is prepared by extracting, concentrating, drying and smashing into powder, the soft capsule has no toxicity or side effects, and the soft capsule further has two efficacies of treatment and prevention and simultaneously has the function of being used with operation therapy, thereby having the beneficial effects of promoting the discharge of residual stones, alleviating the symptoms, and the like.

The invention relates to application of cytokines IP-10 and IL-6 as a combined marker in preparation of a kit for diagnosis or monitoring of tuberculosis. The cytokines and a combination thereof provided by the invention can realize detection of cytokines in the plasma of newly diagnosed tuberculosis patients, can significantly improve the diagnosibility of pulmonary tuberculosis, and are conducive to prognosis of diseases and treatment situations thereof.

To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes.

To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes.